search results for 
Logo

Earnings structure

Group net income (before special items)¹ rose by 12% to €1,051 million (2012: €938 million). Growth in constant currency was 14%. Earnings per share (before special items)¹ rose to €5.88 (2012: €5.42 ). This represents an increase of 8% at actual rates and of 11% in constant currency. The weighted average number of shares was 178.7 million.

Including special items, Group net income was €1,011 million (2012: €926 million) and earnings per share were €5.66 (2012: €5.35).

Inflation had no significant effect on results of operations in 2013.

Group EBITDA² was €3,888 million (2012: €3,851 million). This corresponds to an increase of 3% in constant currency. Group EBIT² was €3,045 million (2012: €3,075 million). This corresponds to an increase of 1% in constant currency.

The EBIT development by business segment was as follows:

  • Fresenius Medical Care EBIT was €1,699 million (2012: €1,813 million), a decrease of 3% in constant currency. The EBIT margin was 15.4% (2012: 16.9%), primarily due to the lower reimbursement rates for Medicare dialysis patients based on budget cuts in the United States (sequestration).
  • Fresenius Kabi EBIT was €926 million (2012: €934 million), an increase of 1% in constant currency. EBIT includes €31 million remediation costs (net of Calea book gain) to meet FDA requirements at the Grand Island, USA, and Kalyani, India, plants. The EBIT margin was 19.8% (2012: 20.6%) excluding Fenwal, and 18.5% including Fenwal.
  • Fresenius Helios achieved excellent EBIT growth of 21% to €390 million (2012: €322 million). The EBIT margin was 11.5% and clearly exceeded the previous year’s level (2012: 10.1%).
  • Fresenius Vamed increased EBIT by 8% to €55 million (2012: €51 million). The EBIT margin was 5.4% (2012: 6.0%).
1Net income attributable to the shareholders of Fresenius SE & Co. KGaA. 2013 before integration costs for Fenwal (€40 million). 2012 before a non-taxable investment gain (€34 million) and other one-time costs (€17 million) at Fresenius Medical Care as well as one-time costs (€29 million) related to the offer to the shareholders of Rhön-Klinikum AG 22013 before integration costs for Fenwal (€54 million); 2012 before one-time costs related to the takeover offer to the shareholders of Rhön-Klinikum AG (€6 million) and other one-time costs at Fresenius Medical Care (€86 million)
Back to:
Sales

QUICKFINDER

History

Tools